ADCC-Enhanced Anti-Human HER2 ([vic-]trastuzumab) Antibody (CAT#: BioBet-CB-033LX) Datasheet

ERBB2

erb-b2 receptor tyrosine kinase 2

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.

NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu

Cell Biology, Immunology,

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

[vic-]trastuzumab

Humanized

Human

ADCC-Enhanced Anti-Human HER2 ([vic-]trastuzumab) Antibody is derived from clone [vic-]trastuzumab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the HER2, and it is intended for the research of Breast cancer .

Breast cancer

Similar to the parental antibody [vic-]trastuzumab, ADCC-Enhanced Anti-Human HER2 ([vic-]trastuzumab) Antibody targets to the antigen HER2, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.